Adverse events Visual field defects · people with epilepsy
It is very uncertain whether VGB changes adverse events Visual field defects compared with CBZ monotherapy (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · adults and children with focal seizures
1 finding from 1 review
Intervention not reported
Adverse events · adults and children with focal seizures
1 finding from 1 review
Intervention not reported
Adverse events · adults and children with generalised tonic‐clonic seizures with or without other seizure types
1 finding from 1 review
Serious adverse events · adults and children with drug‐resistant focal epilepsy
Any dose of lacosamide probably leads to higher serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Dizziness · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes adverse events: dizziness compared with placebo (very low certainty).
1 finding from 1 review
Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · people with drug‐resistant focal epilepsy
Carisbamate may leads to higher adverse events: somnolence compared with placebo (low certainty).
1 finding from 1 review
Number of children with clinical adverse events (any) · children undergoing neurodiagnostic procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with drug‐resistant epilepsy
1 finding from 1 review
Adverse drug events · people with ADHD and epilepsy
Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of people experiencing adverse drug events compared with risperidone and previous ASM only (low certainty).
1 finding from 1 review
Adverse drug events · people with ADHD and epilepsy
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · people with drug‐resistant focal epilepsy
Brivaracetam showed no clear difference in proportion of participants who experienced any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · people with focal epilepsy
Losigamone showed no clear difference in the proportion of participants experiencing any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Time to treatment failure due to adverse events All participants Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine leads to lower time to treatment failure due to adverse events All participants… compared with phenytoin (primary outcomes) (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
Brivaracetam may leads to higher proportion of participants who experienced adverse events leading to… compared with placebo (low certainty).
1 finding from 1 review
Adverse events during treatment period · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with treatment‐emergent adverse events (TEAEs) ‐ Leading to discontinuation during the treatment period № of participants: 36 (1 RCT) · people with newly diagnosed epilepsy
It is very uncertain whether clonazepam changes proportion of participants with treatment‐emergent adverse events… compared with carbamazepine (very low certainty).
1 finding from 1 review
RR 2.61 [0.8, 8.52]
Studies not reported
Very low